CY1105953T1 - Συνθεσεις για απελευθερωση συνδυασμων φαρμακων - Google Patents
Συνθεσεις για απελευθερωση συνδυασμων φαρμακωνInfo
- Publication number
- CY1105953T1 CY1105953T1 CY20071100100T CY071100100T CY1105953T1 CY 1105953 T1 CY1105953 T1 CY 1105953T1 CY 20071100100 T CY20071100100 T CY 20071100100T CY 071100100 T CY071100100 T CY 071100100T CY 1105953 T1 CY1105953 T1 CY 1105953T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compositions
- drug combinations
- release
- competitive
- agents
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000890 drug combination Substances 0.000 title abstract 2
- 230000036963 noncompetitive effect Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Συνθέσεις που περιλαμβάνουν ουσίες-οχήματα απελευθέρωσης έχοντας σταθερώς συσχετισμένες μετ' αυτών μη-ανταγωνιστικές συνθέσεις δύο ή περισσότερων παραγόντων, τέτοιων όπως αντινεοπλασματικών παραγόντων, είναι χρήσιμες στο να επιτυγχάνονται μη-ανταγωνιστικές δράσεις όταν χορηγούνται συνδυασμοί φαρμάκων.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32667101P | 2001-10-03 | 2001-10-03 | |
US34152901P | 2001-12-17 | 2001-12-17 | |
US35675902P | 2002-02-15 | 2002-02-15 | |
CA002383259A CA2383259A1 (en) | 2002-04-23 | 2002-04-23 | Synergistic compositions |
US40198402P | 2002-08-07 | 2002-08-07 | |
US40873302P | 2002-09-06 | 2002-09-06 | |
PCT/CA2002/001500 WO2003028696A2 (en) | 2001-10-03 | 2002-10-03 | Compositions for delivery of drug combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1105953T1 true CY1105953T1 (el) | 2011-04-06 |
Family
ID=32475852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100100T CY1105953T1 (el) | 2001-10-03 | 2007-01-25 | Συνθεσεις για απελευθερωση συνδυασμων φαρμακων |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP1432402B1 (el) |
JP (2) | JP4778679B2 (el) |
AT (1) | ATE345775T1 (el) |
AU (1) | AU2002331480B2 (el) |
CA (1) | CA2462369C (el) |
CY (1) | CY1105953T1 (el) |
DE (1) | DE60216305T2 (el) |
DK (1) | DK1432402T3 (el) |
ES (1) | ES2272768T3 (el) |
HK (1) | HK1065714A1 (el) |
IL (2) | IL161214A (el) |
PT (1) | PT1432402E (el) |
WO (1) | WO2003028696A2 (el) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
EP1608338A1 (en) * | 2003-04-02 | 2005-12-28 | Celator Technologies Inc. | Pharmaceutical compositions containing active agents having a lactone group and transition metal ions |
JP2006522026A (ja) * | 2003-04-02 | 2006-09-28 | セレーター ファーマスーティカルズ、インク. | カンプトセシンとフルオロピリミジンとを組み合わせた組成物 |
WO2004087105A1 (en) * | 2003-04-02 | 2004-10-14 | Celator Pharmaceuticals, Inc. | Combination formulations of platinum agents and fluoropyrimidines |
GEP20094620B (en) | 2004-06-01 | 2009-02-25 | Yakult Honsha Kk | Irinotecan preparation |
JP2008506780A (ja) | 2004-07-19 | 2008-03-06 | セレーター ファーマスーティカルズ、インク. | 活性剤放出のための粒子状構築物 |
EP1796689A4 (en) * | 2004-09-20 | 2009-01-14 | British Columbia Cancer Agency | GEMCITABINE FREE OR ENCAPSULATED IN LIPOSOMES ONLY OR IN ASSOCIATION WITH FREE IDARUBICIN OR ENCAPSULATED IN LIPOSOMES |
BRPI0516265A (pt) | 2004-10-06 | 2008-08-26 | Bc Cancer Agency | composição, uso da mesma, método de aumentar a retenção de um agente terapêutico dentro dos lipossomas, formulação lipossomal, e, uso de um agente terapêutico encapsulado lipossomalmente |
WO2007044748A2 (en) * | 2005-10-11 | 2007-04-19 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
WO2007050784A2 (en) * | 2005-10-25 | 2007-05-03 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
WO2007076117A2 (en) * | 2005-12-22 | 2007-07-05 | Celator Pharmaceuticals, Inc. | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
EP2049106A2 (en) * | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2131814A4 (en) * | 2007-02-26 | 2011-08-03 | Wisconsin Alumni Res Found | POLYMIC MICROMS FOR THE RELEASE OF ACTIVE COMPOUNDS |
EP2190409B9 (en) * | 2007-08-16 | 2019-03-06 | Biocompatibles UK Limited | Delivery of drug combinations |
US8486924B2 (en) | 2007-11-28 | 2013-07-16 | Celator Pharmaceuticals, Inc. | Taxane delivery system |
CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
US20110223241A1 (en) | 2008-10-16 | 2011-09-15 | Celator Pharmaceuticals, Inc. | Combination methods and compositions |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
CN107530283A (zh) * | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 组合脂质体药物制剂 |
EP3267975A4 (en) | 2015-03-09 | 2018-08-08 | The Regents of the University of California | Polymer-drug conjugates for combination anticancer therapy |
RU2018105494A (ru) | 2015-07-15 | 2019-08-15 | Селатор Фармасьютикалз, Инк. | Улучшенные системы доставки наночастиц |
CN105434437B (zh) * | 2015-12-01 | 2018-03-02 | 山东大学 | 一种奥沙利铂和伊立替康类药物共载脂质体及其制备方法 |
CN106619509B (zh) * | 2016-12-21 | 2020-02-18 | 山东大学 | 一种奥沙利铂和伊立替康共载载药脂肪乳及其制备方法 |
US20230093147A1 (en) * | 2020-03-09 | 2023-03-23 | President And Fellows Of Harvard College | Methods and compositions relating to improved combination therapies |
US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL26210A (en) * | 1965-08-02 | 1970-12-24 | Merck & Co Inc | Pharmaceutical compositions containing substituted sulphoxides |
JP3213471B2 (ja) * | 1994-04-13 | 2001-10-02 | ポーラ化成工業株式会社 | 薬効成分含有リポソーム製剤の製造方法 |
ES2311451T3 (es) * | 1999-03-24 | 2009-02-16 | The Secretary Of State For Defence | Carbohidratos policationicos como immuestimulantes en vacunas. |
AU777620B2 (en) * | 1999-04-09 | 2004-10-21 | Jessie L.S. Au | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
CA2377385A1 (en) * | 1999-06-03 | 2000-12-14 | Jessie L.S. Au | Methods and compositions for modulating cell proliferation and cell death |
US6352996B1 (en) * | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
ES2258471T3 (es) * | 1999-09-09 | 2006-09-01 | The Regents Of The University Of California | Suministro de liposomas cationicos de taxanos a vasos sanguineos angiogenicos. |
WO2001026627A1 (en) * | 1999-10-14 | 2001-04-19 | 1170535 Ontario Inc. | Liposome encapsulated silver salt compositions |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
ATE277935T1 (de) * | 2000-02-10 | 2004-10-15 | Liplasome Pharma As | Auf lipiden basierende systeme zur arzneistoffabgabe |
EP1265635A1 (en) * | 2000-03-22 | 2002-12-18 | Glaxo Group Limited | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
-
2002
- 2002-10-03 JP JP2003532029A patent/JP4778679B2/ja not_active Expired - Lifetime
- 2002-10-03 DE DE60216305T patent/DE60216305T2/de not_active Expired - Lifetime
- 2002-10-03 CA CA002462369A patent/CA2462369C/en not_active Expired - Lifetime
- 2002-10-03 ES ES02766997T patent/ES2272768T3/es not_active Expired - Lifetime
- 2002-10-03 AU AU2002331480A patent/AU2002331480B2/en not_active Expired
- 2002-10-03 WO PCT/CA2002/001500 patent/WO2003028696A2/en active Application Filing
- 2002-10-03 DK DK02766997T patent/DK1432402T3/da active
- 2002-10-03 EP EP02766997A patent/EP1432402B1/en not_active Expired - Lifetime
- 2002-10-03 AT AT02766997T patent/ATE345775T1/de active
- 2002-10-03 PT PT02766997T patent/PT1432402E/pt unknown
- 2002-10-03 EP EP06009230A patent/EP1693052A1/en not_active Withdrawn
-
2004
- 2004-04-01 IL IL161214A patent/IL161214A/en active IP Right Grant
- 2004-11-10 HK HK04108630A patent/HK1065714A1/xx not_active IP Right Cessation
-
2007
- 2007-01-25 CY CY20071100100T patent/CY1105953T1/el unknown
-
2008
- 2008-01-15 IL IL188774A patent/IL188774A0/en unknown
-
2010
- 2010-02-19 JP JP2010034701A patent/JP4926256B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
PT1432402E (pt) | 2007-02-28 |
HK1065714A1 (en) | 2005-03-04 |
CA2462369A1 (en) | 2003-04-10 |
ATE345775T1 (de) | 2006-12-15 |
AU2002331480B2 (en) | 2007-10-25 |
IL188774A0 (en) | 2008-04-13 |
WO2003028696A2 (en) | 2003-04-10 |
CA2462369C (en) | 2009-12-22 |
EP1432402B1 (en) | 2006-11-22 |
JP2010180210A (ja) | 2010-08-19 |
DK1432402T3 (da) | 2007-03-26 |
ES2272768T3 (es) | 2007-05-01 |
WO2003028696A3 (en) | 2003-07-31 |
JP4778679B2 (ja) | 2011-09-21 |
IL161214A (en) | 2008-06-05 |
DE60216305T2 (de) | 2007-07-05 |
WO2003028696A8 (en) | 2006-09-08 |
EP1693052A1 (en) | 2006-08-23 |
EP1432402A2 (en) | 2004-06-30 |
DE60216305D1 (de) | 2007-01-04 |
JP4926256B2 (ja) | 2012-05-09 |
JP2005508920A (ja) | 2005-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105953T1 (el) | Συνθεσεις για απελευθερωση συνδυασμων φαρμακων | |
CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
IS6658A (is) | Ný efnasambönd | |
WO2004093795A3 (en) | Compositions for delivery of drug combinations | |
PT1263724E (pt) | Novos compostos | |
TR200102911T2 (tr) | Adamantan türevleri. | |
AR028810A1 (es) | Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion | |
MXPA03007837A (es) | Composiciones para suministrar bisfosfonatos. | |
ATE316083T1 (de) | Adamantanderivate | |
ES2184149T3 (es) | Paclitaxeles 6-tio sustituidos. | |
TR200200795T2 (tr) | 5-HT1B antagonistleri olarak piperazin türevleri | |
ATE365703T1 (de) | Substituierte 1,3-diphenylprop-2-en-1-on derivate,deren herstellung und anwendungen | |
MXPA03004549A (es) | Derivados de 3-arilindola y su uso como agonistas del receptor cb2. | |
TR200003108T2 (tr) | İlaç kompozisyonları | |
MXPA03007857A (es) | Compuestos y composiciones para entregar agentes activos. | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
DK0971717T3 (da) | Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler | |
BR0008228A (pt) | Composições de n-benzoil estaurosporinaespontaneamente dispersìveis | |
SE0302573D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
SE9802937D0 (sv) | Novel compounds | |
SE0003476D0 (sv) | Compounds | |
IL172538A0 (en) | Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof | |
SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
DE69933671D1 (de) | Adenosin a1 antagonisten gegen männliche sterilität | |
TR200302134T4 (tr) | 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı. |